SG10201610537VA - Methods of detecting diseases or conditions using circulating diseased cells - Google Patents

Methods of detecting diseases or conditions using circulating diseased cells

Info

Publication number
SG10201610537VA
SG10201610537VA SG10201610537VA SG10201610537VA SG10201610537VA SG 10201610537V A SG10201610537V A SG 10201610537VA SG 10201610537V A SG10201610537V A SG 10201610537VA SG 10201610537V A SG10201610537V A SG 10201610537VA SG 10201610537V A SG10201610537V A SG 10201610537VA
Authority
SG
Singapore
Prior art keywords
conditions
methods
diseased cells
detecting diseases
circulating diseased
Prior art date
Application number
SG10201610537VA
Inventor
Harry Stylli
Original Assignee
Harry Stylli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harry Stylli filed Critical Harry Stylli
Publication of SG10201610537VA publication Critical patent/SG10201610537VA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
SG10201610537VA 2012-06-15 2013-06-14 Methods of detecting diseases or conditions using circulating diseased cells SG10201610537VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261660518P 2012-06-15 2012-06-15

Publications (1)

Publication Number Publication Date
SG10201610537VA true SG10201610537VA (en) 2017-02-27

Family

ID=49758760

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201610537VA SG10201610537VA (en) 2012-06-15 2013-06-14 Methods of detecting diseases or conditions using circulating diseased cells
SG11201408383SA SG11201408383SA (en) 2012-06-15 2013-06-14 Methods of detecting diseases or conditions using circulating diseased cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201408383SA SG11201408383SA (en) 2012-06-15 2013-06-14 Methods of detecting diseases or conditions using circulating diseased cells

Country Status (11)

Country Link
US (2) US20150141260A1 (en)
EP (1) EP2861788B1 (en)
KR (1) KR20150035818A (en)
AU (1) AU2013273984A1 (en)
BR (1) BR112014031414A2 (en)
CA (1) CA2876711A1 (en)
EA (1) EA201590024A1 (en)
IL (1) IL236182A0 (en)
MX (1) MX2014015434A (en)
SG (2) SG10201610537VA (en)
WO (1) WO2013188828A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2946345B1 (en) 2013-01-17 2024-04-03 Personalis, Inc. Methods and systems for genetic analysis
EP3965111A1 (en) 2013-08-30 2022-03-09 Personalis, Inc. Methods and systems for genomic analysis
WO2015051275A1 (en) 2013-10-03 2015-04-09 Personalis, Inc. Methods for analyzing genotypes
WO2015179672A1 (en) * 2014-05-21 2015-11-26 Atherotech, Inc. Methods of isolation of cell free complexes and circulating cell-free nucleic acid
GB201416015D0 (en) * 2014-09-10 2014-10-22 Univ Warwick Biomarker
US10125399B2 (en) 2014-10-30 2018-11-13 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
CN105158390B (en) * 2015-08-31 2017-07-07 广州金域医学检验中心有限公司 A kind of method of quick detection whole blood red blood cell lignocerane monoenoic acid
CN105445360A (en) * 2015-11-30 2016-03-30 南昌大学 Method for quickly detecting dichlorvos in honey through ND-EESI-MS (neutral desorption-extractive electrospray ionization-mass spectrography)
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
JP2018183095A (en) * 2017-04-26 2018-11-22 株式会社エンプラス Method for isolating fetus-derived hemopoietic precursor cell, and method for testing possibility of chromosomal aberration of fetus
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US20200319188A1 (en) * 2019-04-04 2020-10-08 Magarray, Inc. Methods of producing circulating analyte profiles and devices for practicing same

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
CA2359816C (en) 1999-01-06 2010-08-03 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
FR2816411B1 (en) 2000-11-03 2003-07-04 Inst Nat Sante Rech Med MEANS FOR DETECTING THE PATHOLOGICAL TRANSFORMATION OF THE APP PROTEIN AND THEIR APPLICATIONS
DE10291986D2 (en) 2001-05-09 2004-04-15 Biovision Ag Method for the detection of a progressive, chronic dementia disease, associated peptides and detection reagents
US7863012B2 (en) * 2004-02-17 2011-01-04 Veridex, Llc Analysis of circulating tumor cells, fragments, and debris
US20030113910A1 (en) * 2001-12-18 2003-06-19 Mike Levanduski Pluripotent stem cells derived without the use of embryos or fetal tissue
WO2004005921A1 (en) 2002-07-05 2004-01-15 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of tb2 gene and protein for neurodegenerative diseases
FR2844279A1 (en) 2002-09-06 2004-03-12 Inst Nat Sante Rech Med MEANS FOR DETECTING NEURODEGENERATIVE PROCESSES AND THEIR APPLICATIONS
GB0225360D0 (en) 2002-10-31 2002-12-11 Univ London Genetic markers
US20060259991A1 (en) 2003-02-04 2006-11-16 Evotech Neurosciences Gmbh Diagnostic and therapeutic use of scn2b protein for neurodegeneraative diseases
WO2004071269A2 (en) 2003-02-13 2004-08-26 Intellectual Property Consulting Inc. Gene marker and composition for diagnosis and treatment of neurological disorders and diseases and use of the same
EP1704247A2 (en) 2003-10-03 2006-09-27 The Government of the United States of America, represented by the Secretary, Department of Health and Human Services Use of cripto-1 as a biomarker for neurodegenerative disease and method of inhibiting progression thereof
JP2007513337A (en) 2003-11-19 2007-05-24 サトリス， インコーポレイテッド Diagnostic, stratified and monitoring methods for Alzheimer's disease
WO2005050222A1 (en) 2003-11-19 2005-06-02 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of the human sgpl1 gene and protein for neurodegenerative diseases
US20060094064A1 (en) 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
EP1542016A1 (en) * 2003-12-11 2005-06-15 Institut Gustave Roussy PUMA, phosphorylated p53 and p38 map kinase as markers for HIV-1-induced apoptosis in circulating T cells of infected patient
WO2005072340A2 (en) 2004-01-27 2005-08-11 Compugen Ltd. Novel polynucleotides encoding polypeptides and methods using same
WO2005075674A1 (en) 2004-02-04 2005-08-18 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of kcne4 gene and protein for alzheimer disease
US20080051334A1 (en) 2004-04-16 2008-02-28 Evotec Neurosciences Gmbh Diagnostic and Therapeutic Use of Kcnc1 for Neurodegenerative Diseases
ES2471403T3 (en) 2004-04-20 2014-06-26 Sphingotec Gmbh Use of tachykinin precursors and / or their fragments in medical diagnosis
AU2005240669A1 (en) 2004-05-07 2005-11-17 Garvan Institute Of Medical Research Detecting disease association with aberrant glycogen synthase kinase 3-beta expression
EP1745296A2 (en) 2004-05-10 2007-01-24 EVOTEC Neurosciences GmbH Diagnostic and therapeutic use of kcnj6 for alzheimer's disease
WO2005114222A1 (en) 2004-05-13 2005-12-01 Sphingo Tec Gmbh Use of precursors of enkephalins and/or their fragments in medical diagnostics
CA2574727A1 (en) 2004-07-19 2006-02-23 University Of Rochester Biomarkers of neurodegenerative disease
US20070087376A1 (en) 2004-08-30 2007-04-19 Potashkin Judith A Splice variants of pre-mRNA transcripts as biomarkers in idiopathic neurodegenerative diseases
WO2006050475A2 (en) 2004-11-03 2006-05-11 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with neurological diseases
WO2006048778A1 (en) 2004-11-08 2006-05-11 King's College London Markers of predisposition to addictive states
US20060115855A1 (en) 2004-12-01 2006-06-01 Power3 Medical Products, Inc. FK506-binding protein 7 related protein as a biomarker for neurodegenerative disease
US20060115854A1 (en) 2004-12-01 2006-06-01 Power3 Medical Products, Inc. Acetyl-LDL receptor related proteins and peptides as a biomarker for neurodegenerative disease
WO2006061610A2 (en) 2004-12-07 2006-06-15 Electrophoretics Limited Diagnosis of neurodegenerative diseases
GB0426859D0 (en) 2004-12-07 2005-01-12 Proteome Sciences Plc Diagnosis of neurodegenerative disorders
FR2880897B1 (en) * 2005-01-18 2010-12-17 Inst Nat Sante Rech Med METHOD OF DETECTION, NON-INVASIVE, PRENATAL, IN VITRO OF NORMAL HEALTHY CONDITION, HEALTHY CARRIER STATUS OR SICK CARRIER STATUS OF MUCOVISCIDOSIS
US7572592B2 (en) 2005-01-31 2009-08-11 Glycominds Ltd Method for diagnosing multiple sclerosis
US20070141625A1 (en) 2005-02-03 2007-06-21 Santos Jose H Method for assessing risk of and predisposition to development of a pathology related to the presence of anti-epcr autoantibodies
ES2346467T3 (en) 2005-04-06 2010-10-15 Verstappen, Leopold NEURODEGENERATIVE MARKERS FOR DEPRESSION.
GB0512401D0 (en) 2005-06-17 2005-07-27 Randox Lab Ltd Method
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
US20070148661A1 (en) 2005-07-19 2007-06-28 Duke University LSAMP Gene Associated With Cardiovascular Disease
EP1987361A4 (en) 2006-01-30 2009-03-04 Invitrogen Corp Compositions and methods for detecting and quantifying toxic substances in disease states
CA2640748C (en) 2006-02-28 2010-04-20 Phenomenome Discoveries Inc. Methods for the diagnosis of dementia and other neurological disorders
EP1847615A1 (en) 2006-04-18 2007-10-24 Genoscreen Expression and polymorphism of the ornithine transcarbamylase (OTC) gene as markers for diagnosing Alzheimer's disease
US20090305265A1 (en) 2006-04-27 2009-12-10 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
CA2650963C (en) 2006-05-01 2020-09-15 Critical Care Diagnostics, Inc. St2 as a cardiovascular disease marker for high-bmi or impaired renal function patients
WO2007131345A1 (en) 2006-05-12 2007-11-22 The Hospital For Sick Children Genetic risk factor in sod1 and sfrs15 in renal disease, diabetic cataract, cardiovascular disease and longevity
AU2007254243B2 (en) 2006-05-17 2013-06-13 Ludwig Institute For Cancer Research Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
EP2032983A2 (en) 2006-05-24 2009-03-11 Cellumen, Inc. Method for modeling a disease
WO2007147074A2 (en) * 2006-06-14 2007-12-21 Living Microsystems, Inc. Use of highly parallel snp genotyping for fetal diagnosis
DE102006027818A1 (en) 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro multiparameter determination method for the diagnosis and early diagnosis of neurodegenerative diseases
WO2008003826A1 (en) 2006-07-07 2008-01-10 Oy Jurilab Ltd Novel genes and markers in essential arterial hypertension
KR100856375B1 (en) 2006-07-18 2008-09-04 김현기 Marker for diagnosing Neurodegenerative diseases
US7851172B2 (en) 2006-07-25 2010-12-14 University Of Kentucky Research Foundation Biomarkers of mild cognitive impairment and alzheimer's disease
US20080152589A1 (en) 2006-09-08 2008-06-26 Peter Schofield Diagnostics and Therapeutics of Neurological Disease
EP2067040A2 (en) 2006-09-26 2009-06-10 ProteoSys AG Use of at least one isoform of progesterone receptor membrane component 1 (pgrmc1)
WO2008046512A1 (en) 2006-10-16 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Prss23 as a biomarker, therapeutic and diagnostic target
WO2008046510A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Fn1 as a biomarker, therapeutic and diagnostic target
US20100081136A1 (en) 2006-10-16 2010-04-01 Stefan Golz Crtac as a biomarker, therapeutic and diagnostic target
ES2443042T3 (en) 2006-10-16 2014-02-17 Bayer Intellectual Property Gmbh LTBP2 as a biomarker, therapeutic and diagnostic target
US20100159486A1 (en) 2006-11-01 2010-06-24 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions
US20100169988A1 (en) 2006-12-06 2010-07-01 Bernhard Kohli Means and methods for isolating and determining novel targets for the treatment of neurodegenerative, neurological or neuropsychiatric disorders and compositions comprising the same
US8815519B2 (en) 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
WO2008085024A1 (en) 2007-01-12 2008-07-17 Erasmus University Medical Center Rotterdam Identification and detection of peptides relating to specific disorders
CA2677339A1 (en) 2007-02-08 2008-08-14 Powmri Limited Method of diagnosing a neurodegenerative disease
WO2008100596A2 (en) 2007-02-15 2008-08-21 Burnham Institute For Medical Research Biomarkers of neurodegenerative disease
KR101571523B1 (en) 2007-02-21 2015-11-24 디코드 제네틱스 이에이치에프 Genetic susceptibility variants associated with cardiovascular disease
US8101380B2 (en) 2007-03-26 2012-01-24 The United States Of America As Represented By The Secretary Of Health And Human Services Schizophrenia-related isoform of KCNH2 and development of antipsychotic drugs
WO2008120684A1 (en) 2007-03-30 2008-10-09 Yamaguchi University Method for determining prognosis of acute central nervous system disorder
CN101680883A (en) 2007-04-12 2010-03-24 艾匹托普国际股份有限公司 Biomarkers for multiple sclerosis
GB0708075D0 (en) 2007-04-26 2007-06-06 Univ Nottingham Nethods
ES2653851T3 (en) 2007-05-01 2018-02-09 University Of Miami Transcriptomic biomarkers for individual risk assessment in newly developed heart failure
ITRM20070351A1 (en) 2007-06-22 2008-12-23 Istituto Naz Per Le Malattie I GENE CODIFYING AMBER PROTEIN 1 HAVING REGULATORY ACTIVITY OF THE SELF-FAILURE AND DEVELOPMENT OF THE CENTRAL NERVOUS SYSTEM
EP2171089B1 (en) 2007-06-25 2014-01-22 Universität Duisburg-Essen Screening-method for polymorphic markers in htra1 gene in neurodegenerative disorders
US8227201B2 (en) 2007-06-27 2012-07-24 Board Of Trustees Of The Leland Stanford Junior University BETA2-microglobulin and C reactive protein (CRP) as biomarkers for peripheral artery disease
FR2918329B1 (en) 2007-07-06 2009-10-02 Renault Sas COOLING ECOPE FOR MOTOR VEHICLE
ES2443540T3 (en) 2007-07-17 2014-02-19 Metabolon, Inc. Biomarkers for pre-diabetes and methods that use them
WO2009032722A1 (en) 2007-08-29 2009-03-12 The Cleveland Clinic Foundation Carbamylated proteins and risk of cardiovascular disease
US20090275046A1 (en) 2007-08-29 2009-11-05 Power3 Medical Products, Inc. Complement factor H protein as a biomarker of Parkinson's disease
GB0717637D0 (en) 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
FI20070795A0 (en) 2007-10-24 2007-10-24 Faron Pharmaceuticals Oy A new biomarker for monitoring disease development and assessing the effectiveness of therapies
WO2009058168A1 (en) 2007-11-04 2009-05-07 Prediction Sciences Llc Cellular fibronectin as a diagnostic marker in cardiovascular disease and methods of use thereof
US8748113B2 (en) * 2007-11-15 2014-06-10 The Johns Hopkins University Methods for detecting and monitoring circulating cancer stem cells
WO2009068591A2 (en) 2007-11-28 2009-06-04 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Biomarkers for the onset of neurodegenerative diseases
US8506933B2 (en) 2007-11-30 2013-08-13 Msdx, Inc. Methods of detecting a neurological condition via analysis of circulating phagocytes
WO2009074331A2 (en) 2007-12-11 2009-06-18 Julius-Maximilians-Universität Würzburg Early and differential diagnosis test for alzheimer's disease
WO2009075566A1 (en) 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
EP2245457A1 (en) 2008-01-23 2010-11-03 Rigshospitalet Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40
WO2009097450A1 (en) 2008-01-30 2009-08-06 Dexcom. Inc. Continuous cardiac marker sensor system
US20110082203A1 (en) 2008-02-04 2011-04-07 Kevin Ka-Wang Wang Process to diagnose or treat brain injury
AU2008255192A1 (en) 2008-03-22 2009-10-08 Newcastle Innovation Limited Detection of a biomarker of aberrant cells of neuroectodermal origin in a body fluid
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
EP2107377A1 (en) 2008-04-04 2009-10-07 BRAHMS Aktiengesellschaft Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events
US8030097B2 (en) 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
WO2010005750A2 (en) 2008-06-16 2010-01-14 The Regents Of The University Of California Potential prognostic markers and therapeutic targets for neurological disorders
US20100167937A1 (en) 2008-07-08 2010-07-01 Power3 Medical Products, Inc. Multiple forms of Alzheimer's disease based on differences in concentrations of protein biomarkers in blood serum
US20110177509A1 (en) 2008-07-23 2011-07-21 The Washington University Risk factors and a therapeutic target for neurodegenerative disorders
AU2009282117B2 (en) 2008-08-11 2016-05-12 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
GB0818650D0 (en) 2008-10-10 2008-11-19 Uni I Oslo Methods
US20100124756A1 (en) 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
AU2009314145A1 (en) 2008-11-11 2010-05-20 Entelos, Inc. Biomarkers for assessing atherosclerotic potential
US20120094295A1 (en) 2008-11-21 2012-04-19 The Johns Hopkins University Neurodegenerative disease diagnostic compositions and methods of use
IT1392551B1 (en) 2008-11-25 2012-03-09 Bioindustry Park Del Canavese S P A BIOMARCERS FOR DIAGNOSIS AND TO DETECT THE PROGRESSION OF NEURODEGENERATIVE DISEASES, IN PARTICULAR OF AMIOTROPHIC LATERAL SCLEROSIS
NZ628281A (en) 2008-12-09 2016-05-27 Stephanie Fryar Williams Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders
EP4303584A3 (en) * 2010-07-23 2024-04-03 President and Fellows of Harvard College Methods for detecting signatures of disease or conditions in bodily fluids

Also Published As

Publication number Publication date
EP2861788B1 (en) 2018-10-10
EA201590024A1 (en) 2015-05-29
EP2861788A4 (en) 2016-07-27
IL236182A0 (en) 2015-01-29
MX2014015434A (en) 2015-07-14
EP2861788A1 (en) 2015-04-22
US20150141260A1 (en) 2015-05-21
CA2876711A1 (en) 2013-12-19
SG11201408383SA (en) 2015-01-29
AU2013273984A1 (en) 2015-01-22
BR112014031414A2 (en) 2017-06-27
WO2013188828A1 (en) 2013-12-19
US20180238894A1 (en) 2018-08-23
KR20150035818A (en) 2015-04-07

Similar Documents

Publication Publication Date Title
IL236182A0 (en) Methods of detecting diseases or conditions using circulating diseased cells
HK1209793A1 (en) Methods of detecting diseases or conditions
ZA201502433B (en) Methods of host cell modification
GB2531881B (en) Method of isolating circulating tumor cells
IL224321B (en) Methods of detecting diseases or conditions using phagocytic cells
DK2863990T3 (en) MEDICAL MICROELECTRODE
EP2971014A4 (en) Methods of cell culture
IL229463A0 (en) Rapid detection of metabolic activity
EP2596117A4 (en) Methods of detecting kidney-associated diseases or conditions
EP2859356A4 (en) Pathways characterization of cells
HK1214624A1 (en) Cardiac stem cells and methods of identifying and using the same
HK1208503A1 (en) Euglobulin-based method for determining the biological activity of defibrotide
PL2925223T3 (en) Improved methods of assessing metabolic function
GB2525562B (en) Methods for purification of biological cells
EP2844272A4 (en) Methods and compositions for increasing red blood cells
HK1213596A1 (en) Detection of human umbilical cord tissue-derived cells
HK1211498A1 (en) Treatment of sickle cell disease and inflammatory conditions
HK1200355A1 (en) Treatment of red blood cells
SG11201502214PA (en) Adipose tissue cells
EP2912694A4 (en) Methods of forming solar cells
GB201210756D0 (en) Analysis of small RNA
GB201216933D0 (en) Adipose tissue cells
GB201216936D0 (en) Adipose tissue cells
SG10201705083RA (en) Euglobulin-based method for determining the biological activity of defibrotide
GB201217445D0 (en) Preservation of cells